Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy - Top_Thought_Leaders - MDSpire

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

  • By

  • Maria D. Guerrero

  • May 6, 2026

  • 13 min

Share

Top Thought Leaders in Oncology

Brief introduction explaining scope and methodology.

Original Source(s)

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

  • by Maria D. Guerrero

  • May 6, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”